Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Lifecare's analyst fair value per share has been cut from NOK0.65 to NOK0.40, a sizeable reset that directly affects how you might frame risk and reward around the stock. Analysts link this lower target to revised expectations for the business, with more cautious revenue assumptions and updated inputs feeding both optimistic and cautious narratives. As you read on, you will see how these shifting views can help you track the evolving story and what it could mean for your own research on Lifecare.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Several firms, including Deutsche Bank, Baird, Citizens, Barclays, BofA, and Citi, have issued research on Ethos with Buy ratings, which signals confidence in the stock at current levels.
-
Deutsche Bank lifted its price target on Ethos from US$23 to US$24, then to US$30, suggesting the firm sees room for the stock to better reflect its view of the company's prospects.
-
BofA raised its target on Ethos from US$15 to US$18 after what it called a "clean beat & raise" first quarter as a public company, and highlighted management's focus on using AI to manage costs and support fraud control.
-
Citi and BofA both pointed to solid recent reporting, with Citi describing Ethos' Q4 and early Q1 performance as strong, which feeds into more constructive earnings expectations in their models.
🐻 Bearish Takeaways
-
Even with higher targets, research coverage on Ethos still flags AI and regulatory complexity as key risks, which can affect long term growth assumptions and valuation ranges if conditions change.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 5 risks for Lifecare. See which could impact your investment.
What's in the News
-
Lifecare ASA shareholders approved amendments to the Articles of Association at the April 23, 2026 AGM, related to an increase in share capital and adjustments to the company's framework for future equity structure.
-
The company is centralising operations by discontinuing Lifecare Germany GmbH and shifting manufacturing to Bergen, Norway, with chemistry activities moved to Bristol, UK, subject to a 12 month creditor period in Germany.
-
Lifecare received feedback from the Norwegian Medical Products Agency on its clinical investigation application for the CGM implant, with the regulator requesting additional technical documentation before approval. The company is preparing a resubmission.
-
In pre clinical testing, Lifecare reported more than 12 weeks of stable implant performance in dogs without structural signal degradation. The company also appointed Petter Nielsen as CFO from April 1, 2026, succeeding Renete Kaarvik.
How This Changes the Fair Value For Lifecare
-
Fair value per share cut from NOK0.65 to NOK0.40.
-
Revenue growth assumption moved from a 51.30% increase to a 6.01% decline.
-
Net profit margin input adjusted from 20.88% to 21.80%.
-
Future P/E multiple moved from 3.99x to 136.27x, which is a very large increase.
-
Discount rate trimmed from 8.60% to 7.81%.
Never Miss an Update: Follow The Narrative
Narratives connect a company's scientific and commercial story to the assumptions sitting behind its forecasts and fair value. They refresh as new trials, regulatory decisions, and partnerships come through, so you can see how the thesis is changing in real time.
Head over to the Simply Wall St Community and follow the Narrative on Lifecare to stay up to date on:
-
How the TTP collaboration and automated production plans aim to make the CGM implant easier to manufacture and potentially lower unit costs.
-
The role of new sensor chemistry and possible Sanofi commercial rights in shaping future market access for Lifecare's glucose monitoring technology.
-
Key execution risks around in vivo validation, CE marking timelines for human use, and the possibility that partnership milestones or regulatory approvals are delayed.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LIFE.OL .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
